Literature DB >> 20881619

Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs.

Melissa A McDiarmid1, Marc S Oliver, Tracy S Roth, Bonnie Rogers, Carmen Escalante.   

Abstract

OBJECTIVE: To determine the frequency of "signature" chromosomal abnormalities in oncology workers handling anticancer drugs.
METHODS: Peripheral blood from health care personnel (N = 109) was examined with probes for targets on chromosomes 5, 7, and 11. The effect of drug-handling frequency on chromosome abnormalities was assessed.
RESULTS: An excess of structural (0.18 vs 0.02; P = 0.04) and total abnormalities (0.29 vs 0.04; P = 0.01) of chromosome 5 was observed in the high-exposure group compared with the unexposed. Increased incidence rate ratios (IRRs) for abnormalities of chromosome 5 (IRR = 1.24; P = 0.01) and for either chromosome 5 or 7 (IRR = 1.20; P = 0.01) were obtained at 100 handling events. Effect sizes were augmented 2- to 4-fold when alkylating agent handling alone was considered.
CONCLUSIONS: Biologically important exposure to genotoxic drugs is apparently occurring in oncology work settings despite reported use of safety practices.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20881619     DOI: 10.1097/JOM.0b013e3181f73ae6

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  24 in total

1.  Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings.

Authors:  Bettina Kopp; Rudolf Schierl; Dennis Nowak
Journal:  Int Arch Occup Environ Health       Date:  2012-02-05       Impact factor: 3.015

2.  Hazardous drug residue on exterior vial surfaces: evaluation of a commercial manufacturing process.

Authors:  Luci A Power; Paul J M Sessink; Kathy Gesy; Flay Charbonneau
Journal:  Hosp Pharm       Date:  2014-04

3.  Adherence to safe handling guidelines by health care workers who administer antineoplastic drugs.

Authors:  James M Boiano; Andrea L Steege; Marie H Sweeney
Journal:  J Occup Environ Hyg       Date:  2014       Impact factor: 2.155

4.  Impact of robotic antineoplastic preparation on safety, workflow, and costs.

Authors:  Andrew C Seger; William W Churchill; Carol A Keohane; Caryn D Belisle; Stephanie T Wong; Katelyn W Sylvester; Megan A Chesnick; Elisabeth Burdick; Matt F Wien; Michael C Cotugno; David W Bates; Jeffrey M Rothschild
Journal:  J Oncol Pract       Date:  2012-09-25       Impact factor: 3.840

5.  Pilot Evaluation of Dermal Contamination by Antineoplastic Drugs among Hospital Pharmacy Personnel.

Authors:  Chun-Yip Hon; George Astrakianakis; Quinn Danyluk; Winnie Chu
Journal:  Can J Hosp Pharm       Date:  2011-09

6.  Antineoplastic drug contamination in the urine of Canadian healthcare workers.

Authors:  Chun-Yip Hon; Kay Teschke; Hui Shen; Paul A Demers; Scott Venners
Journal:  Int Arch Occup Environ Health       Date:  2015-01-28       Impact factor: 3.015

7.  Hazardous Drug Contamination of Drug Preparation Devices and Staff: A Contamination Study Simulating the Use of Chemotherapy Drugs in a Clinical Setting.

Authors:  Evan Call; Brian Bill; Chad McLean; Nathan Call; Allyn Bernkopf; Craig Oberg
Journal:  Hosp Pharm       Date:  2017-08-20

Review 8.  Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs.

Authors:  Christine Roussel; Kristine L Witt; Peter B Shaw; Thomas H Connor
Journal:  Mutat Res Rev Mutat Res       Date:  2017-08-24       Impact factor: 5.657

9.  Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device.

Authors:  Paul J M Sessink; Jason Trahan; Joseph W Coyne
Journal:  Hosp Pharm       Date:  2013-03

10.  Antigenotoxic effect of lipoic acid against mitomycin-C in human lymphocyte cultures.

Authors:  Fatma Unal; Gokce Taner; Deniz Yuzbasioglu; Serkan Yilmaz
Journal:  Cytotechnology       Date:  2012-11-07       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.